Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Matrix Biol. 2016 Nov 29;60-61:190–205. doi: 10.1016/j.matbio.2016.11.008

Figure 3. TEV treatment of ASCs activates MAPK signaling.

Figure 3

Western blots and densitometric analysis of phosphorylated and total ERK (a) and JNK (b). * p<0.05 vs. all other conditions. c) Immunofluorescence of α-SMA (red) and nuclei (blue) of ASCs treated with TEVs in the presence and absence of a function-blocking TGF-β antibody (α-TGFβ), the MEK inhibitor PD98059, and the JNK inhibitor SP600125. Scale bar = 50 um. d) Quantification of α-SMA levels by image analysis. * p<0.05 vs. Ctrl, # p<0.05 vs. α-TGFβ, ● p<0.05 vs. SP600125. One, two, and three symbols indicate p<0.05, p<0.01, and p<0.001, respectively.

HHS Vulnerability Disclosure